


**Atlantic Canada  
Cardiovascular Conference 2023**



**AGENDA**

**— 2023 —**

**Friday, June 2**

Sir Charles Tupper Building  
Dalhousie Campus  
Theatre B

**08:00 - 08:05**      **Introductions and Learning objectives**      **Simon Jackson**

**Heart Failure Topics**

**08:05 - 08:35**      **HF Champions: An Atlantic Effort**      **Kim Anderson / Rody Pike**  
 HSF of Canada has identified improving Heart Failure care as a primary initiative to improve cardiovascular disease outcomes. Dr Anderson and colleagues will present some preliminary data outlining the impact of HF in Atlantic Canada, and address how this collaborative Atlantic effort will work to advance HF outcomes.

**08:35 - 09:05**      **Making HF Care Better in Practice: The Cape Breton Experience**      **David McFarlane**  
 Drs Paul Morrison and David McFarlane were challenged to address the HF outcomes in patients hospitalized in the Eastern Zone of NSHA. Their collaborative initiative using early access to imaging and consultation, with a rapid titration clinic has dramatically changed HF outcomes in a short period. They will share this how this QA initiative has made major impact on the outcomes of HF care in Cape Breton.

**09:05 - 09:35**      **HFpEF: How Does SGLT2 Inhibition Work in HFpEF?**      **Richard Crowell**  
 Is this medication class a new standard of care, or is more data required? Can we predict what guidelines might say?

**09:35 - 10:00**      **Refreshment Break and Industry Partner Booths**

**Chronic CAD: how we change the natural history**

Disease modifying therapy for chronic cad includes aggressive LDL lowering, antiplatelet therapy, and ACEi or ARB as background therapy. Recent trials have shown evidence of meaningful impact on disease progression through anti-inflammatory agents, and the addition of highly purified omega 3 fatty acids, yet clinical uptake of these agents has been slow, and quite varied between provinces. We will review the evidence supporting the use of eicosapent ethyl and colchicine, and try and indicate who might most benefit from these additional therapies.

**10:00 - 10:30**      **A Summary of Benefits From ASA, Statins (LDL lowering) and ACE/ARB in 20 Minutes From a Master**      **Iqbal Bata**  
 Dr. Bata will overview the huge body of literature supporting in summary format indicating the expected benefit of these agents in patients with chronic CAD

|                            |  |                 |
|----------------------------|--|-----------------|
| 10:30 - 11:00              | <b>Eicosapent Ethyl: How And When to Use?</b><br>Dr. D'Astous will review the key outcome data from the pivotal clinical trials supporting use, and identify the trial eligible patients. He will add his personal prescribing practices in a province where pharmacare coverage is available, highlighting when he adds this new agent.   | Michel D'Astous |
| 11:00 - 11:30              | <b>Colchicine: When to Add?</b><br>Colchicine: When to add on? Dr. MacDonald has been an early adopter of the use of colchicine in the treatment of CAD. Given the medication choices available, where should colchicine be added? What care is required to prescribe.   | Paul MacDonald  |
| 11:30 - 11:50              | <b>Clinical Cases for Discussion and Debate</b><br>Dr. Jackson will present 3 cases for audience feedback and presenter input as to how to manage next.  | Simon Jackson   |
| 11:50 - 12:50              | <b>Lunch Break and Industry Partner Booths</b>   |                 |
| <b>Echo and Myopathies</b> |  |                 |
| 12:50 - 13:20              | <b>Mavacamtam for HCM: How Does it Work, Who Will Benefit, and What Does / Will it Cost?</b>   | Andrew Moeller  |
| 13:20 - 13:50              | <b>Clinical Recognition of Amyloid Heart Disease: Echo and Clinical Pearls</b>   | Doug Hayami     |
| 13:50 - 14:10              | <b>How Can Exercise Stress Echo Help Clinical Decision Making When Ischemia is Not The Primary Question</b><br>What are the clinical questions and scenarios where an stress echo can help clarify cardiac diagnoses unrelated to ischemia? Are there situations when the stress echo won't help address the question you have posed?  | Dan Belliveau   |
| 14:20 - 14:45              | <b>Refreshment Break and Industry Partner Booths</b>   |                 |
| <b>Cath Lab Update</b>     |  |                 |
| 14:45 - 15:15              | <b>Triclip For TR: Can We "Trilluminate" The Way Forward?</b><br>Dr. El-Khateeb will review the recent data supporting the use of a tri-clip device to reduce tricuspid regurgitation. We have had a very early experience in Halifax. Who should be referred, to whom, and what workup is required in advance? We hope to address your question of identifying the correct patient for consideration of this procedure. | Osama Elkhateeb |
| 15:15 - 15:45              | <b>PFO: How, Who and When to Close?</b><br>What should be done before considering a referral for PFO closure for a TIA or stroke? What are other rare indications for PFO closure in clinical practice?  | Joseph Kim      |
| 15:45 - 16:00              | <b>Wrap up-evaluations</b>   | Simon Jackson   |



**DALHOUSIE  
UNIVERSITY**

FACULTY OF MEDICINE  
Continuing Professional  
Development

Educationally approved/co-sponsored by Dalhousie University Continuing Professional Development and Medical Education.

In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers.

As an accredited provider, Dalhousie University Continuing Professional Development and Medical Education, designates this continuing professional development activity for up to **5.75** credit hours as an accredited group learning Section 1 activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found online at [edhub.ama-assn.org](http://edhub.ama-assn.org).

